Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Lineage Cell Therapeutics is a biotechnology business based in the US. Lineage Cell Therapeutics stocks (LCTX.US) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $2.89 – a decrease of 2.27% over the previous week. Lineage Cell Therapeutics employs 70 staff and has a trailing 12-month revenue of around $11.9 million.
Promoted
National Bank Direct Brokerage
Finder Award
Interactive Brokers
| Latest market close | $1.29 |
|---|---|
| 52-week range | $1.02 - $1.79 |
| 50-day moving average | $1.39 |
| 200-day moving average | $1.34 |
| Wall St. target price | $5.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.14 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $1.29 from 2023-05-26
| 1 week (2023-05-23) | -2.27% |
|---|---|
| 1 month (2023-04-28) | -5.15% |
| 3 months (2023-03-02) | -7.19% |
| 6 months (2022-11-30) | -11.03% |
| 1 year (2022-05-27) | -1.53% |
|---|---|
| 2 years (2021-05-28) | -45.57% |
| 3 years (2020-05-29) | 46.59% |
| 5 years (2018-05-30) | 2.22 |
| Revenue TTM | $11.9 million |
|---|---|
| Gross profit TTM | $14 million |
| Return on assets TTM | -9.33% |
| Return on equity TTM | -30.69% |
| Profit margin | -198.77% |
| Book value | $0.41 |
| Market capitalisation | $219.5 million |
TTM: trailing 12 months
We're not expecting Lineage Cell Therapeutics to pay a dividend over the next 12 months.
Lineage Cell Therapeutics's shares were split on a 3:1 basis on 31 October 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Lineage Cell Therapeutics shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Lineage Cell Therapeutics shares which in turn could have impacted Lineage Cell Therapeutics's share price.
Over the last 12 months, Lineage Cell Therapeutics's shares have ranged in value from as little as $1.02 up to $1.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Lineage Cell Therapeutics's is 1.6791. This would suggest that Lineage Cell Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc.
Your guide to how ETFs work and whether this type of investment is right for you.
Read more…
The best stock trading app for beginners is easy to use and offers free trades.
Read more…
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
Read more…We show you the best prepaid credit cards in Canada, whether you’re looking for a prepaid card with no fees, cash back rewards, or travel perks, or more.
This guide provides step-by-step instructions on how to buy Sui, lists some exchanges where you can get it and provides daily price data on (SUI).
Compare apps like Nyble in Canada to access emergency funding.
Your guide to buying and financing a car in Canada with RightRide.
Your guide to bad credit car loans in BC and how to find the right financing for your needs.
Compare six ways to finance a camera in Canada, including options for good and bad credit.
This guide provides step-by-step instructions on how to buy Pepe, lists some exchanges where you can get it and provides daily price data on (PEPE).
Compare lenders to find the best personal loan in Saskatchewan for your needs.
Compare interest rates and eligibility requirements of bad credit loans in Winnipeg.
Teaching teenagers how to budget can be a tricky task. 7 experts give their best tips on how to budget for teenagers.
